Health Care [ 9/12 ] | Biotechnology [ 37/73 ]
NASDAQ | Common Stock
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases.
It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED).
The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022.
Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 25 | -1.79 Decreased by -163.24% | -0.91 Decreased by -96.70% |
| May 12, 25 | -0.89 Decreased by -61.82% | -0.94 Increased by +4.94% |
| Mar 17, 25 | -0.86 Decreased by -6.17% | -0.87 Increased by +1.15% |
| Nov 12, 24 | -0.78 Increased by +52.50% | -0.82 Increased by +4.88% |
| Aug 8, 24 | -0.68 Increased by +80.54% | -0.71 Increased by +4.23% |
| May 13, 24 | -0.55 Decreased by -48.65% | -0.67 Increased by +17.91% |
| Mar 19, 24 | -0.81 Increased by +84.42% | -0.79 Decreased by -2.53% |
| Nov 14, 23 | -1.64 Increased by +64.30% | -0.60 Decreased by -173.68% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -23.09 M Decreased by -32.05% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -22.97 M Decreased by -72.56% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 40.00 K Decreased by -98.24% | -22.23 M Decreased by -72.34% | Decreased by -55.59 K% Decreased by -9.71 K% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -20.18 M Decreased by -187.63% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -17.49 M Decreased by -8.42% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -13.31 M Decreased by -77.43% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 2.28 M Increased by +N/A% | -12.90 M Decreased by -262.14 K% | Decreased by -566.87% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -7.01 M Decreased by -358.72 K% | Decreased by N/A% Decreased by N/A% |